Adalimumab in the treatment of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 12, Issue 12, 2012, Pages 1679-1686

  Voulgari, Paraskevi V ^a   Kaltsonoudis, Evripidis ^a   Papagoras, Charalampos ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adalimumab; Anti TNF ; Drug comparison; Efficacy; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO;

ARTICLE; CANCER RISK; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUPUS LIKE SYNDROME; LYMPHOMA; META ANALYSIS (TOPIC); MONOTHERAPY; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT INDICATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84869417617     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.721771     Document Type: Article

References (67)

1. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611-16
2. Welsing PM, Van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17
3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis. based on the 1987 American. College of Rheumatology criteria: A systematic review. Semin. Arthritis Rheum 2006;36:182-8
4. Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6:1349-60
5. Giles JT, Bathon JM. Management of rheumatoid arthritis: Synovitis. In: RHEUMATOLOGY, Hochberg MC (ed). 4th edition. Mosby Elsevier, Philadelphia, PA; USA, 2008;pp 887-90
6. Smolen Js, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
7. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9
8. Verstappen SM, Jacobs JW, Van Der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9
9. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2011; 70:1519
10. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2012; [Epub ahead of print]
11. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37
12. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-50
13. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008;372(9636):375-82
14. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum 2006; 54:702-10
15. Bang LM, Keating GM. Adalimumab: A review of its use in rheumatoid arthritis. BioDrugs 2004;18:121-39
16. Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem 1999;275:98-108
17. Adalimumab. EMA Summary of product characteristics 2012
18. Zikou AK, Argyropoulou MI, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol 2006;33:219-23
19. Døhn UM, Ejbjerg B, Boonen A, et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: Results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8
20. Bernal Rivera L, Guerrero Aznar MD, Monzon et al. [Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital]. Efectividad y seguridad de adalimumab y etanercept en artritis reumatoide en un hospital de tercer nivel. Farm Hosp 2006;30:223-9
21. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45
22. De Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: Leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010;29:517-24
23. Hetland ML, Christensen IJ, Tarp U, et al. All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
24. Greenberg JD, Reed G, Decktor D, et al. On behalf of the CORRONA investigators: A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42
25. Bazzani C, Filippini M, Caporali R, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. Autoimmun. Rev 2009; 8:260-5
26. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 2009;1173:837-46
27. Markatseli TE, Alamanos Y, Saougou I, et al. Survival of TNF-alpha antagonists in rheumatoid arthritis: A long-term study. Clin Exp Rheumatol 2012; 30:31-8
28. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229-34
29. Iannone F, Gremese E, Atzeni F, et al. Gruppo Italiano di Studio sulle Early Arthritides (GISEA). Longterm Retention of Tumor Necrosis Factor-alpha Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: AN Appraisal of Predictors. J Rheumatol 2012;39:1179-84
30. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40
31. Brocq O, Roux CH, Albert C, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54
32. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012; [Epub ahead of print]
33. Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300
34. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011;13(Suppl 1):S2
35. Infliximab. EMA Summary of product characteristics 2012
36. Exarchou SA, Voulgari PV, Markatseli TE, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009;38:328-31
37. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumor necrosis factor therapy. Ann Rheum Dis 2008; 67:567-70
38. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-85
39. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;17:52
40. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45
41. Keystone EC. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of long-term data. J. Rheumatol 2011;38:1552-62
42. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331-9
43. Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011;70:1401-6
44. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31
45. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis 2012; [Epub ahead of print]
46. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73
47. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5
48. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin. Infect. Dis 2004;39:1254-5
49. Gomez-Reino JJ, Carmona L, Valverde VR, et al. BIOBADASER Group: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7
50. Dixon WG, Hyrich KL, Watson KD, et al. BSR biologics register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis 2010;69:522-8
51. Tubach F, Salmon D, Ravaud P, et al. Research Axed on Tolerance of Biotherapies Group: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94
52. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. BIOBADASER Group: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72
53. Gomez-Reino JJ, Carmona L, Angel Descalzo M. BIOBADASER Group: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61
54. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45
55. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: A systematic review of the literature. Clin. Lymphoma Myeloma 2008;8:87-93
56. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701
57. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95
58. Askling J, Van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9
59. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5
60. Carmona L, Abasolo L, Descalzo MA, et al. BIOBADASER Study Group; EMECAR Study Group. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin. Arthritis Rheum 2011;41:71-80
61. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J. Rheumatol 2005;32:2130-5
62. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904
63. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis 2010;69:400-8
64. Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: Efficacy and safety for approved indications. Expert Opin Drug Saf 2012;11:121-39
65. Certolizumab. EMA Summary of product characteristics 2012
66. Etanercept. EMA Summary of product characteristics 2012
67. Golimumab. EMA Summary of product characteristics 2012